Lowered guidance puts damper on Endo's Q1 results
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals' net income rose by more than a half in the first quarter to $60.4 million as products acquired in its takeover of Indevus continued to add to its revenues.